Granted Patent B2

US 10,272,606 · App. 14/278,367 · Granted Apr 30, 2019

Abstract

Claims (20)

1. A biomedical implant, comprising:

an expandable tubular scaffold comprising a plurality of polymer struts, wherein the polymer struts are interconnected, define a plurality of deformable cells and have an average thickness of no more than 150 μm, and

a coating disposed on the polymer struts, the coating including at least one polymer and a crystalline macrolide immunosuppressive drug,

wherein the polymer struts comprise a fiber-reinforced polymer composite material, the fiber-reinforced polymer composite material comprising a bioabsorbable polymer material and a bioabsorbable reinforcement fiber material, wherein the fiber-reinforced polymer composite material is not located in the coating and wherein the fiber material includes reinforcement fibers that are longitudinally aligned along a center axis of the polymer struts.

2. The biomedical implant of claim 1 , wherein the reinforcement fiber material is bioabsorbable glass.

3. The biomedical implant of claim 1 , wherein the reinforcement fiber material is distributed throughout the polymer struts.

4. The biomedical implant of claim 1 , wherein the fiber-reinforced polymer composite material has a tensile modulus that is at least five times, at least three times, or at least two times of a tensile modulus of the bioabsorbable polymer.

5. The biomedical implant of claim 1 , wherein the fiber-reinforced polymer composite material has a tensile strength that is at least five times, at least three times, or at least two times of a tensile strength of the bioabsorbable polymer.

6. The biomedical implant of claim 1 , wherein the fiber-reinforced polymer composite material comprises from 0.1 wt % to 15 wt % of the reinforcement fiber material.

7. The biomedical implant of claim 1 , wherein the bioabsorbable polymer material is selected from the group consisting of polylactides (PLA); poly(lactide-co-glycolide) (PLGA); polyanhydrides; polyorthoesters; poly(N-(2-hydroxypropyl) methacrylamide); poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); poly(d-lactide) (DPLA); polyglycolide (PGA); poly(dioxanone) (PDO); poly(glycolide-co-trimethylene carbonate) (PGA-TMC); poly(l-lactide-co-glycolide) (PGA-LPLA); poly(dl-lactide-co-glycolide) (PGA-DLPLA); poly(l-lactide-co-dl-lactide) (LPLA-DLPLA); poly(glycolide-co-trimethylene carbonate-co-dioxanone) (PDO-PGA-TMC), poly(lactic acid-co-caprolactone) (PLACL), and mixtures or co-polymers thereof.

8. The biomedical implant of claim 7 , wherein the bioabsorbable polymer material is PLGA.

9. The biomedical implant of claim 1 , wherein the polymer struts have anisotropic elastic modulus.

10. The biomedical implant of claim 9 , wherein the polymer struts have an average longitudinal elastic modulus and an average lateral elastic modulus, the average longitudinal elastic modulus being greater than the average lateral elastic modulus.

11. The biomedical implant of claim 9 , wherein the average longitudinal elastic modulus is at least three times, at least five times, or at least ten times the average lateral elastic modulus.

12. The biomedical implant of claim 1 , wherein more than 50%, more than 70%, or more than 90% of the reinforcement fiber material in the polymer struts are longitudinally aligned.

13. The biomedical implant of claim 1 , wherein the polymer struts are not structurally reinforced with a metal material.

14. The biomedical implant of claim 1 , further comprising a pharmaceutical agent incorporated to the tubular scaffold.

15. The biomedical implant of claim 14 , wherein the pharmaceutical agent is rapamycin.

16. The biomedical implant of claim 14 , wherein the pharmaceutical agent is impregnated in the polymer struts.

17. The biomedical implant of claim 14 , wherein at least a portion of the tubular scaffold is covered with a coating comprising the pharmaceutical agent.

Assignments (6)